The Board of Pharmacy has received notice of the following product recall:

Losartan & Hydrochlorothiazide Tablets
50 mg / 12.5 mg 90ct
NDC# 33342-050-10

LOT #	EXP. DATE
BLK719A	19-Sep
BLK720A	19-Sep
BLK721A	19-Sep
BLK722A	19-Sep
BLK723A	19-Sep
BLK724A	19-Sep
BLK725A	19-Oct
BLK726A	19-Oct
BLK804A	20-Jan
BLK806A	20-Jan
BLK825A	21-Oct
BLK826A	21-Oct

Losartan & Hydrochlorothiazide
100 mg / 12.5 mg 90ct
NDC# 33342-051-10

LOT #	EXP. DATE
BLL801A	19-Dec
BLL802A	19-Dec
BLL803A	19-Dec

Losartan & Hydrochlorothiazide Tablets
100 mg / 25 mg 90ct
NDC# 33342-052-10

LOT #	EXP. DATE
BLM716A	19-Jul
BLM717A	19-Jul
BLM719A	19-Aug
BLM720A	19-Aug
BLM721A	19-Sep

LOT #	EXP. DATE
BLM722A	19-Sep
BLM723A	19-Oct
BLM724A	19-Oct
BLM725A	19-Oct
BLM726A	19-Nov
BLM802A	19-Dec
BLM803A	19-Dec
BLM825A	21-Sep
BLM826A	21-Sep
BLM827A	21-Sep

Losartan Potassium Tablets
50 mg 90ct
NDC# 33342-045-10

LOT #	EXP. DATE
BLI711A	19-Nov

Losartan Potassium Tablets
50 mg 1000ct
NDC# 33342-045-44

LOT #	EXP. DATE
BLI710A	19-Nov

Macleods Pharmaceuticals Limited is initiating a consumer level recall on Losartan Potassium 50mg Tablets and Losartan and Hydrochlorothiazide Tablets 50mg/12.5mg, 100mg/12.5mg, and 100mg/25mg. This recall is based on detection of trace amounts of an unexpected impurity (NMBA) found in finished product of the above mentioned lots. The impurity detected is N-Nitroso-N-Methyl-4- aminobutyric acid (NMBA). The impurity is a known animal and potential human carcinogen. The batches were distributed by Macleods Pharma USA, Inc. from November 10, 2017, through February 5, 2019.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.